V
30.51
-0.45 (-1.45%)
| Previous Close | 30.96 |
| Open | 31.03 |
| Volume | 108,043 |
| Avg. Volume (3M) | 895,629 |
| Market Cap | 2,378,095,872 |
| Price / Earnings (TTM) | 98.42 |
| Price / Earnings (Forward) | 23.36 |
| Price / Sales | 4.99 |
| Price / Book | 1.89 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | 5.42% |
| Operating Margin (TTM) | 6.62% |
| Diluted EPS (TTM) | 0.310 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Total Debt/Equity (MRQ) | 4.31% |
| Current Ratio (MRQ) | 4.73 |
| Operating Cash Flow (TTM) | 75.10 M |
| Levered Free Cash Flow (TTM) | 66.49 M |
| Return on Assets (TTM) | 1.39% |
| Return on Equity (TTM) | 2.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Veracyte, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 104.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (Needham, 67.16%) | Buy |
| Median | 45.00 (47.49%) | |
| Low | 45.00 (Stephens & Co., 47.49%) | Buy |
| 45.00 (Craig-Hallum, 47.49%) | Buy | |
| 45.00 (Guggenheim, 47.49%) | Buy | |
| Average | 47.00 (54.05%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 32.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 26 Mar 2025 | 45.00 (47.49%) | Buy | 31.05 |
| Craig-Hallum | 20 Mar 2025 | 45.00 (47.49%) | Buy | 31.84 |
| Guggenheim | 25 Feb 2025 | 45.00 (47.49%) | Buy | 33.46 |
| Needham | 25 Feb 2025 | 51.00 (67.16%) | Buy | 33.46 |
| 29 Jan 2025 | 51.00 (67.16%) | Buy | 44.44 | |
| UBS | 25 Feb 2025 | 49.00 (60.60%) | Buy | 33.46 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |